Last edition
News about "Servier"
Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma
Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.
Servier | 13/05/2026 | By News Bureau | 125
BioMed X Launches First Research Team in France to Advance AI-Driven Antibody Design
BioMed X launches AI-focused antibody research team in France, aiming to accelerate development of next-generation biologic therapies for cancer and immune diseases.
Servier | 21/04/2026 | By News Bureau
Servier Strikes USD 2.5 Billion Deal to Buy Day One Biopharmaceuticals
French drugmaker Servier has agreed to acquire US-based Day One Biopharmaceuticals in an all-cash deal valued at approximately USD 2.5 billion, as the company seeks to strengthen its presence in rare oncology and brain tumour therapies.
Servier | 07/03/2026 | By Darshana | 138
Servier to Acquire KER-0193 from Kaerus Bioscience in Deal Worth Up to USD 450 Million
Servier has signed a definitive agreement to acquire KER-0193 from Kaerus Bioscience, a potential first-in-disease treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder.
Servier | 08/09/2025 | By Mrinmoy Dey | 271
Servier and IDEAYA Biosciences have entered into an exclusive license agreement to globally develop and commercialise darovasertib, a potential first-in-class therapy for uveal melanoma, with Servier taking rights outside the US and IDEAYA retaining US rights.
Servier | 02/09/2025 | By Mrinmoy Dey | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy